Chest
Recent Advances in Chest MedicineManagement of Idiopathic Pulmonary Fibrosis in the Elderly Patient
Section snippets
How Should a Confident Diagnosis Be Made in the Elderly Patient?
IPF is one of many potential diagnoses for a patient with newly recognized ILD. Therefore, accurately diagnosing IPF remains one of the most basic, yet critical steps in providing optimal care for the elderly patient with ILD.6, 7 The American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association consensus statement on the diagnosis and management of IPF provides a useful diagnostic algorithm for evaluating a patient with possible IPF.8
What Is the Impact of Disease Complications and Comorbidities?
It is well established that the prognosis of IPF is significantly worse in elderly patients than in younger patients.14, 15 There are a number of potential explanations, including a more aggressive disease course in the elderly, lead-time bias with or without a delay in diagnosis, and a more significant impact of IPF-associated comorbidities on outcomes in elderly patients. A variety of comorbidities and complications16 (Table 2) can have a profound impact on quality of life and outcomes,
What Are Key Considerations and Challenges for Disease Management in the Elderly Patient?
Once a confident diagnosis of IPF has been attained, optimal management must balance standard-of-care measures with the patient's overall health status as well as the patient's wishes, desires, and expectations. For serial monitoring of health status, it is usual practice to see patients with IPF every 3 to 6 months. At each visit, consideration should be given to pulmonary function testing, a 6-min walk test (6MWT), and oxygen titration walk study.28, 29, 30, 31, 32 However, clinical testing
What Are Current Treatment Considerations?
Finding effective pharmacologic treatment of IPF has mostly proven elusive despite the completion of many clinical trials.7, 36 Medical therapies prescribed for patients with IPF have ranged from corticosteroids to cytotoxic drugs or various combinations, but these were previously adopted in the absence of robust clinical trial results.36, 37 Indeed, immunosuppressive therapies that were suggested and commonly administered prior to publication of the current American Thoracic Society/European
What Are Important Prognostic Considerations?
IPF is a heterogeneous disorder with a clinical course that varies from prolonged periods of stability to episodes of rapid progression8, 14; therefore, clinicians must carefully consider many factors when providing patients with a prognosis. Patients with a lesser degree of fibrotic change on HRCT scan are likely to have a better survival with relatively stable lung function when compared with those with HRCT scan changes that indicate “definite” UIP, a greater degree of fibrotic change, or
How Can Patient-Centered Care and Personalized Management Be Provided?
Traditionally, the care of patients with IPF has largely been driven by a disease-centered model, which assumes that treating the disease treats the patient and, thus, leads to improved quality and quantity of life. However, adopting a patient-centered care model may be far more effective, especially for managing older patients with IPF.71 In the elderly patient population, IPF occurs in the context of accumulating age-related comorbidities. Therefore, evaluating elderly patients for treatable
When and How Should Disease-Focused Therapies Be Transitioned to Supportive and Palliative Care?
Symptom management and palliation should be a component of patient care from the time that the initial diagnosis is established.73 When patients have progressive lung function loss and worsening quality of life despite a disease-centered approach with antifibrotic therapies and other interventions, management should increasingly focus on patient support and symptom control, which are integral aspects of palliative care. Pulmonary rehabilitation, supplemental oxygen use, cough suppression,
Summary
The prevalence of IPF is highest in the population of affected patients who are elderly, making optimal IPF management in this group an important priority for their health-care providers. IPF can be effectively managed even in the “oldest old” (Table 4). Critical steps include an accurate and timely diagnosis that minimizes risk of harm; careful assessment of disease status; provision of disease-specific, supportive, and palliative care as needs evolve; and appropriate monitoring. Additionally,
Acknowledgments
Financial/nonfinancial disclosures: The authors have reported to the following conflicts of interest: Dr Meyer is a consultant for InterMune and Medimmune in the field of IPF, and he has received research funding from Actelion Pharmaceuticals Ltd; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; FibroGen, Inc; InterMune; and the National Institutes of Health in the field of IPF. Dr Danoff participates in an industry advisory committee for Boehringer Ingelheim GmbH and the ASCEND Mortality
References (74)
- et al.
Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans
Mech Ageing Dev
(2007) - et al.
Frailty: a basic and clinical challenge for the future
- et al.
Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study
Chest
(2010) - et al.
Combined pulmonary fibrosis and emphysema syndrome: a review
Chest
(2012) - et al.
Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis
Chest
(2006) - et al.
Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis
Respir Med
(2010) - et al.
Obstructive sleep apnea is common in idiopathic pulmonary fibrosis
Chest
(2009) - et al.
IPFnet Investigators. Anti-acid therapy and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomized controlled trials
Lancet Respir Med
(2013) - et al.
Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis
Respir Med
(2009) - et al.
Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study
Respir Med
(2014)
Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response
Chest
Assessment of current practice in the diagnosis and therapy of idiopathic pulmonary fibrosis
Respir Med
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Lancet
Immunosuppressive therapy for autoimmune lung diseases
Immunol Allergy Clin North Am
A consensus document for the selection of lung transplant candidates: 2014-An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
J Heart Lung Transplant
Lung transplantation in patients 70 years old or older: have outcomes changed after implementation of the lung allocation score?
J Thorac Cardiovasc Surg
Outcomes after hospitalization in idiopathic pulmonary fibrosis: a cohort study
Chest
Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study
Lancet Respir Med
Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure
Chest
Frailty, inflammation and the elderly
Biogerontology
Incidence and prevalence of idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
Interstitial lung disease in the elderly: pathogenesis, diagnosis and management
Sarcoidosis Vasc Diffuse Lung Dis
Diagnosis and management of interstitial lung disease
Transl Respir Med
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management
Am J Respir Crit Care Med
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly
Lupus
Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacy
Sarcoidosis Vasc Diffuse Lung Dis
Preoperative nutrition status and postoperative outcome in elderly general surgery patients: a systematic review
JPEN J Parenter Enteral Nutr
Collaborative radiologic and histopathologic assessment of fibrotic lung disease
Radiology
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model
Am J Respir Crit Care Med
A multidimensional index and staging system for idiopathic pulmonary fibrosis
Ann Intern Med
Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases
Curr Opin Pulm Med
Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease
Eur Respir J
High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis
Eur Respir J
Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients
Eur Respir J
Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis
Eur Respir J
Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy?
Eur Respir J
Cited by (0)
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.